Granted Patent
B2
US 12,297,219 · App. 17/841,185 · Granted May 13, 2025
Phosphorodiamidate morpholino oligomers
Inventors:
Baozhong Cai (Cambridge, MA); Mitchell Martini (Cambridge, MA); Katie Thomas (Cambridge, MA); Ross Shimabuku (Cambridge, MA)
Assignee:
Sarepta Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.
Claims (116)
1. A compound of Formula (X):
or a pharmaceutically acceptable salt thereof, wherein
R 1 is a support-medium, and
R 2 is, independently at each occurrence, selected from the group consisting of:
and
wherein R 2 is at each position from 1 to 25 and 5′ to 3′:
Position No. 5′ to 3′
R 2
1
DPG
2
T
3
T
4
DPG
5
PC
6
PC
7
T
8
PC
9
PC
10
DPG
11
DPG
12
T
13
T
14
PC
15
T
16
DPG
17
PA
18
PA
19
DPG
20
DPG
21
T
22
DPG
23
T
24
T
25
PC.
2. The compound of claim 1 , wherein the compound of Formula (X) is of Formula (Xa):
or a pharmaceutically acceptable salt thereof, wherein
R 1 is a support-medium, and
R 2 is, independently at each occurrence, selected from the group consisting of:
and
wherein R 2 is at each position from 1 to 25 and 5′ to 3′:
Position No. 5′ to 3′
R 2
1
DPG
2
T
3
T
4
DPG
5
PC
6
PC
7
T
8
PC
9
PC
10
DPG
11
DPG
12
T
13
T
14
PC
15
T
16
DPG
17
PA
18
PA
19
DPG
20
DPG
21
T
22
DPG
23
T
24
T
25
PC.
Assignments (2)
SECURITY INTEREST
Recorded May 7, 2025
From: SAREPTA THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 071218/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 7, 2025
From: CAI, BAOZHONG; MARTINI, MITCHELL; THOMAS, KATIE; SHIMABUKU, ROSS
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070154/0732 →
Continuity (7)
Continuation
16302529
Provisional Application
62508256
· May 18, 2017
Provisional Application
62357166
· Jun 30, 2016
Provisional Application
62357134
· Jun 30, 2016
Provisional Application
62341049
· May 24, 2016
Provisional Application
62340953
· May 24, 2016
References Cited (174)
US 5034506A
· Summerton et al.
· 1991
[cited by applicant]
US 5142047A
· Summerton et al.
· 1992
[cited by applicant]
US 5166315A
· Summerton et al.
· 1992
[cited by applicant]
US 5185444A
· Summerton et al.
· 1993
[cited by applicant]
US 5217866A
· Summerton et al.
· 1993
[cited by applicant]
US 5506337A
· Summerton et al.
· 1996
[cited by applicant]
US 5521063A
· Summerton et al.
· 1996
[cited by applicant]
US 5698685A
· Summerton et al.
· 1997
[cited by applicant]
US 6355640B1
· Akahane et al.
· 2002
[cited by applicant]
US 6670461B1
· Wengel et al.
· 2003
[cited by applicant]
US 6794499B2
· Wengel et al.
· 2004
[cited by applicant]
US 7034133B2
· Wengel et al.
· 2006
[cited by applicant]
US 7053207B2
· Wengel
· 2006
[cited by applicant]
US 7060809B2
· Wengel et al.
· 2006
[cited by applicant]
US 7084125B2
· Wengel
· 2006
[cited by applicant]
US 7569575B2
· Sorensen et al.
· 2009
[cited by applicant]
US 7572582B2
· Wengel et al.
· 2009
[cited by applicant]
US 7807816B2
· Wilton et al.
· 2010
[cited by applicant]
US 7960541B2
· Wilton et al.
· 2011
[cited by applicant]
US 8067571B2
· Weller et al.
· 2011
[cited by applicant]
US 8076476B2
· Reeves et al.
· 2011
[cited by applicant]
US 8232384B2
· Wilton et al.
· 2012
[cited by applicant]
US 8299206B2
· Fox et al.
· 2012
[cited by applicant]
US 8450474B2
· Wilton et al.
· 2013
[cited by applicant]
US 8455634B2
· Wilton et al.
· 2013
[cited by applicant]
US 8455635B2
· Wilton et al.
· 2013
[cited by applicant]
US 8455636B2
· Wilton et al.
· 2013
[cited by applicant]
US 8476423B2
· Wilton et al.
· 2013
[cited by applicant]
US 8486907B2
· Wilton et al.
· 2013
[cited by applicant]
US 8524880B2
· Wilton et al.
· 2013
[cited by applicant]
US 8637483B2
· Wilton et al.
· 2014
[cited by applicant]
US 8865883B2
· Sazani et al.
· 2014
[cited by applicant]
US 8871918B2
· Sazani et al.
· 2014
[cited by applicant]
US 8969551B2
· Ueda
· 2015
[cited by applicant]
US 9018368B2
· Wilton et al.
· 2015
[cited by applicant]
US 9024007B2
· Wilton et al.
· 2015
[cited by applicant]
US 9035040B2
· Wilton et al.
· 2015
[cited by applicant]
US 9175286B2
· Wilton et al.
· 2015
[cited by applicant]
US 9228187B2
· Wilton et al.
· 2016
[cited by applicant]
US 9234198B1
· Sazani et al.
· 2016
[cited by applicant]
US 9249416B2
· Wilton et al.
· 2016
[cited by applicant]
US 9416361B2
· Iversen et al.
· 2016
[cited by applicant]
US 9422555B2
· Wilton et al.
· 2016
[cited by applicant]
US 9434948B2
· Sazani et al.
· 2016
[cited by applicant]
US 9441229B2
· Wilton et al.
· 2016
[cited by applicant]
US 9447415B2
· Wilton et al.
· 2016
[cited by applicant]
US 9447416B2
· Sazani et al.
· 2016
[cited by applicant]
US 9447417B2
· Sazani et al.
· 2016
[cited by applicant]
US 9453225B2
· Sazani et al.
· 2016
[cited by applicant]
US 9469664B2
· Hanson et al.
· 2016
[cited by applicant]
US 9506058B2
· Kaye
· 2016
[cited by applicant]
US 9605262B2
· Wilton et al.
· 2017
[cited by applicant]
US 9758783B2
· Wilton et al.
· 2017
[cited by applicant]
US 9944926B2
· Linsley et al.
· 2018
[cited by applicant]
US 9994851B2
· Wilton et al.
· 2018
[cited by applicant]
US RE47691E
· Wilton et al.
· 2019
[cited by applicant]
US RE47751E
· Wilton et al.
· 2019
[cited by applicant]
US RE47769E
· Wilton et al.
· 2019
[cited by applicant]
US 20080227742A1
· Dmochowski et al.
· 2008
[cited by applicant]
US 20100292458A1
· Bühler et al.
· 2010
[cited by applicant]
US 20110263686A1
· Wilton et al.
· 2011
[cited by applicant]
US 20130211062A1
· Watanabe et al.
· 2013
[cited by applicant]
US 20140256926A1
· Damha et al.
· 2014
[cited by applicant]
US 20140303238A1
· Linsley et al.
· 2014
[cited by applicant]
US 20140330006A1
· Hanson et al.
· 2014
[cited by applicant]
US 20150197786A1
· Osborne et al.
· 2015
[cited by applicant]
US 20160040162A1
· Bestwick et al.
· 2016
[cited by applicant]
US 20160076033A1
· Torii et al.
· 2016
[cited by applicant]
US 20180163205A1
· Wilton et al.
· 2018
[cited by applicant]
US 20180271993A1
· Passini et al.
· 2018
[cited by applicant]
US 20190127738A1
· Sazani et al.
· 2019
[cited by applicant]
US 20190270994A1
· Wilton et al.
· 2019
[cited by applicant]
US 20190276480A1
· Cai et al.
· 2019
[cited by applicant]
US 20190292208A1
· Cai et al.
· 2019
[cited by applicant]
US 20190323010A1
· Wilton et al.
· 2019
[cited by applicant]
US 20190359982A1
· Kaye
· 2019
[cited by applicant]
US 20200040020A1
· Cai et al.
· 2020
[cited by applicant]
US 20200040337A1
· Kaye
· 2020
[cited by applicant]
US 20200080079A1
· Cai et al.
· 2020
[cited by applicant]
US 20220112491A1
· Cai et al.
· 2022
[cited by applicant]
US 20220364093A1
· Bestwick et al.
· 2022
[cited by applicant]
CA 3024153A1
· 2017
[cited by applicant]
CA 3024182A1
· 2017
[cited by applicant]
CA 3025339A1
· 2017
[cited by applicant]
JP 2015506669A
· 2015
[cited by applicant]
JP 2016517279A
· 2016
[cited by applicant]
JP 2016521119A
· 2016
[cited by applicant]
JP 2019518748A
· 2019
[cited by applicant]
JP 2019518832A
· 2019
[cited by applicant]
JP 2019523754A
· 2019
[cited by applicant]
KR 20130118227A
· 2013
[cited by applicant]
KR 20190013844A
· 2019
[cited by applicant]
KR 20190015311A
· 2019
[cited by applicant]
KR 20190020674A
· 2019
[cited by applicant]
WO WO199002749A1
· 1990
[cited by applicant]
WO WO2004043977A2
· 2004
[cited by applicant]
WO WO2006000057A1
· 2006
[cited by applicant]
WO WO2009064471A1
· 2009
[cited by applicant]
WO WO2010115993A1
· 2010
[cited by applicant]
WO WO2011150324A1
· 2011
[cited by applicant]
WO WO2011150408A2
· 2011
[cited by applicant]
WO WO2012043730A1
· 2012
[cited by applicant]
WO WO2013053928A1
· 2013
[cited by applicant]
WO WO2013082551A1
· 2013
[cited by applicant]
WO WO2014153240A2
· 2014
[cited by applicant]
WO WO2017205496A1
· 2017
[cited by applicant]
WO WO2017205513A1
· 2017
[cited by applicant]
WO WO2017205879A2
· 2017
[cited by applicant]
WO WO2017205880A1
· 2017
[cited by applicant]
Alul, R.H., et al., “Oxalyl-CPG: A Labile Support for Synthesis of Sensitive Oligonucleotide Derivatives,” Nucleic Acids Research 19(7):1527-1532, Oxford University Press, United Kingdom (Apr. 1991).
[cited by applicant]
Atherton, E., et al., “Letter: Polyamide Supports for Polypeptide Synthesis,” Journal of the American Chemical Society, 97(22):6584-6585, American Chemical Society, United States (Oct. 1975).
[cited by applicant]
Atherton, E., et al., “The Polyamide Method of Solid Phase Peptide and Oligonucleotide Synthesis,” Bioorganic Chemistry 8(3):351-370, Elsevier, Netherlands (Sep. 1979).
[cited by applicant]
Atherton, E., et al., “Peptide Synthesis. Part 2. Procedures for Solid-phase Synthesis Using Nα-fluorenylmethoxycarbonylamino-acids on Polyamide Supports. Synthesis of Substance P and of Acyl Carrier Protein 65-74 Decap…
[cited by applicant]
Bayer, E., et al., “A New Support for Polypeptide Synthesis in Columns,” Tetrahedron Letters 51:4503-4505, Elsevier, Netherlands (Nov. 1970).
[cited by applicant]
Berg, R.H., et al., “Long-chain polystrene-grafted polyethylene film matrix: A new support for solid phase peptide synthesis,” Journal of the American Chemical Society 111(20):8024-8026, American Chemical Society, Unite…
[cited by applicant]
Bonora, G.M., et al., “A Liquid-Phase Process Suitable for Large-Scale Synthesis of Phosphorothioate Oligonucleotides,” Organic Process Research & Development 4(3):225-231, American Chemical Society, United States (2000…
[cited by applicant]
Cirak, S., et al., “Exon Skipping and Dystrophin Restoration in Patients With Duchenne Muscular Dystrophy After Systemic Phosphorodiamidate Morpholino Oligomer Treatment: An Open-label, Phase 2, Dose-escalation Study,” …
[cited by applicant]
Daniels, S.B., et al., “Membranes as Solid Supporters for Peptide Synthesis,” Tetrahedron Letters 30:4345-4348, Elsevier, Netherlands (1989).
[cited by applicant]
Eliel, E.L., and Wilen, S.H., eds., “Chirality in Molecules Devoid of Chiral Center,” Chapter 14 in
[cited by applicant]
Geysen, H.M., et al., “Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid,” Proceedings of the National Academy of Sciences of the United States of America 81(13):3998-4…
[cited by applicant]
Goemans, N.M., et al., “Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy,” The New England Journal of Medicine 364(16):1513-1522, Massachusetts Medical Society, United States (Apr. 2011).
[cited by applicant]
Gravert, D.J., et al., “Organic Synthesis on Soluble Polymer Supports: Liquid-phase Methodologies,” Chemical Reviews 97(2):489-510, American Chemical Society, United States (Apr. 1997).
[cited by applicant]
Houghten, R.A, “General Method for the Rapid Solid-phase Synthesis of Large Numbers of Peptides: Specificity of Antigen-antibody Interaction at the Level of Individual Amino Acids,” Proceedings of the National Academy o…
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2017/040318, International Search Authority, United States, mailed on Sep. 26, 2017, 10 pages.
[cited by applicant]
Johnson, R., et al., “New Light Labile Linker for Solid Phase Synthesis of 2′-O-Acetalester Oligonucleotides and Applications to Sirna Prodrug Development,” Bioorganic & Medicinal Chemistry Letters 21(12):3721-3725, Els…
[cited by applicant]
Kent, S.B.H., and Merrifield, R.B., “Preparation and Properties of Tert-butyloxycarbonylaminoacy1-4-(Oxymethyl) Phenylacetamidomethyl-(Kel F-g-styrene) Resin, an Insoluble, Noncrosslinked Support for Solid Phase Peptide…
[cited by applicant]
Kinali, M., et al., “Local Restoration of Dystrophin Expression With the Morpholino Oligomer AVI-4658 in Duchenne Muscular Dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study,” The Lan…
[cited by applicant]
March, J., ed., “Stereochemistry,” Chapter 4 in
[cited by applicant]
Parr, W., and Grohmann, K., “Solid-phase Peptide Synthesis on an Inorganic Matrix Having Organic Groups on the Surface,” Applied Chemistry (International ed. in English) 11(4):314-315, Wiley-VCH, Germany (Apr. 1972).
[cited by applicant]
Scott, R.P.W., et al., “Use of Resin Coated Glass Beads in the Form of a Packed Bed for the Solid Phase Synthesis of Peptides,” Journal of Chromatographic Science 9(10):577-591, Oxford University Press, United Kingdom (…
[cited by applicant]
Summerton, J., and Weller, D., “Morpholino Antisense Oligomers: Design, Preparation, and Properties,” Antisense & Nucleic Acid Drug Development 7(3):187-195, Mary Ann Liebert, Inc., United States (Jun. 1997).
[cited by applicant]
Van Deutekom, J.C., et al., “Local Dystrophin Restoration with Antisense Oligonucleotide PRO051,” The New England Journal of Medicine 357(26):2677-2686, Massachusetts Medical Society, United States (Dec. 2007).
[cited by applicant]
Van Rietschoien, et al., “Simultaneous Synthesis of Two Peptide Analogs on Different Insoluble Supports,” in Peptides, pp. 113-116, Y. Wolman, Ed., Wiley and Sons, United States (1974).
[cited by applicant]
Wright, P., et al., “Large Scale Synthesis of Oligonucleotides via Phosphoramidite Nucleosides and a High-loaded Polystyrene Support,” Tetrahedron Letters 34(21):3373-3376, Elsevier, Netherlands (1993).
[cited by applicant]
Office Action mailed Feb. 6, 2020, in U.S. Appl. No. 16/302,018, Cai, B., et al., filed Nov. 15, 2018, 15 pages.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2017/034284, WIPO, Switzerland, mailed on Nov. 27, 2018, 6 pages.
[cited by applicant]
International Search Report and Written opinion for International Application No. PCT/US2017/034284, European Patent Office, Netherlands, mailed on Jul. 27, 2017, 9 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/034235, European Patent Office, Netherlands, mailed Jul. 31, 2017, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/034235, WIPO, Switzerland, mailed Nov. 27, 2018, 6 pages.
[cited by applicant]
Notice of Allowance mailed Apr. 29, 2020, in U.S. Appl. No. 16/303,356, Cai, B. et al., filed Nov. 20, 2018.
[cited by applicant]
Singh, S.K., et al., “LNA (locked nucleic acids): Synthesis and High-affinity Nucleic acid Recognition,” Chemical Communications 4:455-456, Royal Society of Chemistry, United Kingdom (1998).
[cited by applicant]
Koshkin, A.A., et al., “LNA (Locked Nucleic Acids): Synthesis of the Adenine, Cytosine, Guanine, 5-methylcytosine, Thymine and Uracil Bicyclonucleoside Monomers, Oligomerisation and Unprecedented Nucleic Acid Recognitio…
[cited by applicant]
Wengel, J., “Synthesis of 3′-c- and 4′-c-branched Oligodeoxynucleotides and the Development of Locked Nucleic Acid (LNA),” Accounts of Chemical Research 32(4):301-310, American Chemical Society, United States (Apr. 1999…
[cited by applicant]
Obika, S., et al., “Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel Bicyclic Nucleosides having a Fixed C3, -endo Sugar Puckering,” Tetrahedron Letters 38(50):8735-8738, Elsevier, United Kingdom (Dec. 1997).
[cited by applicant]
Obika, S., et al., “Stability and Structural Features of the Duplexes Containing Nucleoside Analogues With a Fixed N-type Conformation, 2′-0,4′- C-methyleneribonucleosides,” Tetrahedron Letters 39:5401-5404, Elsevier, U…
[cited by applicant]
Obika, S., et al., “Synthesis and Properties of 3′-amino-2′,4′-BNA, a Bridged Nucleic Acid with a N3′—P5′ Phosphoramidate Linkage,” Bioorganic Medicinal Chemistry 16(20):9230-9237, Elsevier, United Kingdom (Oct. 2008).
[cited by applicant]
Iyer, R.P., et al., “The Automated Synthesis of Sulfur-Containing Oligodeoxyribonucleotides Using 3H-1,2-Benzodithiol-3-one 1,1-Dioxide as a Sulfur-Transfer Reagent,” The Journal of Organic Chemistry 55(15):4693-4699, A…
[cited by applicant]
Yoo, H.B., et al., “2′-o-methyl-modified Phosphorothioate Antisense Oligonucleotides Have Reduced Non-specific Effects in Vitro,” Nucleic Acids Research 32(6):2008-2016, Oxford University Press, United Kingdom (Apr. 200…
[cited by applicant]
Martin, P., “A New Access to 2-O-Alkylated Ribonucleosides and Properties of 2-O-Alkylated Oligoribonucleotides,” Helvetica Chimica Acta 78(2):486-504, John Wiley & Sons, Switzerland (Aug. 1995).
[cited by applicant]
Yamada, T., et al., “Synthesis of 2′-O-[2-(N-methylcarbamoyl)ethyl]ribonucleosides Using Oxa-michael Reaction and Chemical and Biological Properties of Oligonucleotide Derivatives Incorporating These Modified Ribonucleo…
[cited by applicant]
Office Action mailed Apr. 28, 2020, in U.S. Appl. No. 16/302,443, Cai, B. et al., filed Nov. 16, 2018.
[cited by applicant]
Restriction Requirement mailed Jan. 27, 2020, in U.S. Appl. No. 16/302,443, Cai, B. et al., filed Nov. 16, 2018, 9 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/040311, International Search Authority, United States, mailed Dec. 8, 2017, 10 pages.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2017/040311, International Search Authority, United States, mailed Nov. 27, 2018, 10 pages.
[cited by applicant]
Virta, P., et al., “Solid-Supported Synthesis of Oligomeric Bioconjugates,” Tetrahedron 59(28):5137-5174, Pergamon, England (Jul. 2003).
[cited by applicant]
Notice of Allowance mailed Sep. 25, 2020, in U.S. Appl. No. 16/302,018, Cai, B., et al., filed Nov. 15, 2018, 9 pages.
[cited by applicant]
Notice of Allowance mailed Dec. 21, 2020, in U.S. Appl. No. 16/302,443, Cai, B. et al., filed Nov. 16, 2018, 7 pages.
[cited by applicant]
Notice of Allowance mailed Nov. 2, 2020, in U.S. Appl. No. 16/302,443, Cai, B., et al., filed Nov. 16, 2018, 10 pages.
[cited by applicant]
Notice of Allowance mailed Aug. 14, 2020, in U.S. Appl. No. 16/303,356, Cai, B., et al., filed Nov. 20, 2018, 9 pages.
[cited by applicant]
Office Action mailed Nov. 22, 2021, in U.S. Appl. No. 17/098,935, Cai, B., et al., filed Nov. 16, 2020, 8 pages.
[cited by applicant]
Notice of Allowance mailed Mar. 16, 2022, in U.S. Appl. No. 17/098,935, Cai, B., et al., filed Nov. 16, 2020, 8 pages.
[cited by applicant]